Im­pel Phar­ma con­sid­ers bank­rupt­cy, as­set sales de­spite mi­graine nasal spray quar­ter­ly rev­enue jump

There is “sub­stan­tial doubt” that Im­pel Phar­ma­ceu­ti­cals can con­tin­ue, and the biotech, which has one mi­graine nasal spray treat­ment, is con­sid­er­ing bank­rupt­cy or sell­ing off its as­sets, ac­cord­ing to SEC fil­ings.

Im­pel re­port­ed prod­uct rev­enue of $6.6 mil­lion for the sec­ond quar­ter — a jump from $2.8 mil­lion at the same time last year thanks to in­creased sales of its nasal spray — but it’s not enough to keep up with the near­ly $20 mil­lion it spent on com­mer­cial op­er­a­tions and mar­ket­ing the drug dur­ing the quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER